Cardiometabolic Health was Eli Lilly’s largest product and service line in fiscal 2025, bringing in $33.86B of $65.18B (52%).
| Product and Service | FY 2016 | FY 2018 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Cardiometabolic Health | $14.78B | $21.85B | $33.86B | ||
| Net Product Revenue | — | — | — | ||
| Mounjaro | $4.83B | $8.95B | $13.65B | ||
| Diabetes | — | — | — | ||
| Oncology | $3.80B | — | $5.35B | ||
| Trulicity | — | — | $2.91B | ||
| Other Cardiometabolic Health | $2.74B | $2.68B | — | ||
| Zepbound | $176.00M | $4.93B | — | ||
| Trulicity® | — | — | — | ||
| Verzenio | $2.51B | $3.42B | — | ||
| Verzenio® | — | — | — | ||
| Immunology | — | — | $2.96B | ||
| Humalog® | — | — | — | ||
| Taltz | $1.83B | — | $2.33B | ||
| Taltz® | — | — | — | ||
| Other | $459.00M | — | — | ||
| Other Product Total | — | — | — | ||
| Jardiance | $1.60B | $1.60B | $1.58B | ||
| Other Oncology | $1.29B | $1.62B | $1.89B | ||
| Alimta® | — | — | — | ||
| Cialis® | — | — | — | ||
| Humulin® | — | — | — | ||
| Collaboration & Other Revenue | — | — | — | ||
| Forteo® | — | — | — | ||
| Basaglar | — | — | — | ||
| Erbitux® | — | — | — | ||
| Other Product | — | — | — | ||
| Other Immunology | $226.00M | — | $631.00M | ||
| Cyramza® | — | — | — | ||
| Neuroscience | — | — | — | ||
| Trajenta (Bi) | — | — | — | ||
| Other Neuroscience | — | — | — | ||
| Other Diabetes | — | — | — | ||
| Cymbalta® | — | — | — | ||
| Zyprexa® | — | — | — | ||
| Olumiant® | — | — | — | ||
| Emgality® | — | — | — | ||
| Total | $34.24B | $45.04B | $65.18B |
Eli Lilly brought in $65.18B from its nine product and service lines in fiscal 2025, the year ended December 31, 2025. Eli Lilly regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $45.04B. Cardiometabolic Health was the largest at $33.86B (52.0%), ahead of Mounjaro at $13.65B (20.9%) and Oncology at $5.35B (8.2%). The other six lines brought in $12.31B combined.
Compared with fiscal 2024, Cardiometabolic Health grew fastest, up 55.0% to $33.86B, while Jardiance fell the most, down 1.0% to $1.58B.
Eli Lilly began breaking out Trulicity in fiscal 2025, when it brought in $2.91B. Eli Lilly stopped reporting Zepbound ($4.93B in fiscal 2024), Verzenio ($3.42B in fiscal 2024), Other Cardiometabolic Health ($2.68B in fiscal 2024) and one other as separate lines.
United States was Eli Lilly’s largest region in fiscal 2025, bringing in $43.48B of $65.18B (67%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $18.19B | $21.79B | $30.38B | $43.48B | ||||||||||||
| Europe | $4.30B | $6.18B | $6.92B | $11.56B | ||||||||||||
| Rest Of World | $2.85B | $2.95B | $4.27B | $6.06B | ||||||||||||
| Other Foreign Countries | — | — | — | — | ||||||||||||
| Japan | $1.75B | $1.67B | $1.82B | $2.13B | ||||||||||||
| China | $1.45B | $1.54B | $1.66B | $1.95B | ||||||||||||
| Total | $28.54B | $34.13B | $45.04B | $65.18B |
Eli Lilly brought in $65.18B from its five regions in fiscal 2025, the year ended December 31, 2025. That was up 44.7% from $45.04B in fiscal 2024. United States was the largest at $43.48B (66.7%), ahead of Europe at $11.56B (17.7%) and Rest Of World at $6.06B (9.3%). The other two regions brought in $4.08B combined.
Compared with fiscal 2024, Europe grew fastest, up 67.0% to $11.56B. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $28.54B to $65.18B, a compound annual growth rate of 31.7%. United States' share of the total rose from 63.7% to 66.7%.
Eli Lilly (LLY) reports its revenue by product and service and by geography. In fiscal 2025, Cardiometabolic Health was its largest product and service line, bringing in $33.86B (52.0% of the total), followed by Mounjaro at $13.65B (20.9%).
Cardiometabolic Health was Eli Lilly's largest product and service line in fiscal 2025, bringing in $33.86B, or 52.0% of the $65.18B total across its nine product and service lines.
United States was Eli Lilly's largest region in fiscal 2025, bringing in $43.48B, or 66.7% of the $65.18B total across its five regions.
Among Eli Lilly's regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 67.0% from $6.92B to $11.56B.
Every figure comes from Eli Lilly's annual financial filings, as reported. Each line keeps the name Eli Lilly gives it, and years follow its fiscal calendar.
Eli Lilly's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.